Altimmune Inc

Altimmune insiders are buying options amid volatility, signaling confidence that the company’s valuation may lag its long‑term pipeline potential.

Altimmune insider buying signals confidence in a $75 M offering and Phase 2 obesity trial progress, boosting investor sentiment and future growth prospects.

Altimmune insider buying signals cautious optimism ahead of 2026 obesity & NASH data; executives balance RSU gains with tax‑cover sales.

Altimmune insider buying surges as CEO‑elect Pisano Wayne buys 5,000 shares near a 52‑week low, backing the company’s FDA Breakthrough Therapy designation and promising clinical‑stage growth.